Peptides vs HGH: differences, evidence and safety

HGH is the hormone itself, and it adds lean mass: 2.1 kg in older adults. GH-releasing peptides make the pituitary release its own GH; tesamorelin cut belly fat 15.2%. HGH is FDA-approved for GH deficiency. Among the peptides, only tesamorelin is approved, and no adult trial compares them with HGH.

Both headline results come from human trials. In healthy older adults, HGH raised lean mass by 2.1 kg and cut fat mass by 2.1 kg across 18 study groups (Human RCTs, systematic review, n=220). Tesamorelin (Egrifta) reduced visceral (deep belly) fat by 15.2% over 26 weeks in people with HIV, while it rose 5.0% on placebo (Human RCT, n=412). Popular peptides such as ipamorelin and CJC-1295 are not FDA-approved and have only small trials. HGH and every GH-releasing peptide are banned in sport.

Item	HGH (somatropin)	GH-releasing peptides
US FDA status	Approved. Example: Genotropin for adult and child GH deficiency (label). Distributing it for unauthorized uses is a federal crime (21 U.S.C. 333(e))	Tesamorelin is approved as Egrifta WR for HIV lipodystrophy belly fat (label). Sermorelin (Geref) was discontinued in 2008, not for safety reasons (FDA notice). Ipamorelin and CJC-1295 are not approved
Compounding (503A/503B)	Not on FDA’s Category 2 page. Supplied as approved products	Ipamorelin: Category 2 (503B). MK-677: Category 2 (503A and 503B). CJC-1295 and AOD-9604: withdrawn from Category 2, with no category since. Sermorelin and tesamorelin: not listed (FDA, as of 2026-04-22)
WADA	Prohibited at all times under S2 on the 2026 List (WADA). Still prohibited on the 2027 List, in force from 2027-01-01 (USADA)	Prohibited at all times under S2 on the 2026 List, which covers GHRH analogs, secretagogues, GHRPs and GH fragments. The 2027 List keeps them prohibited and adds “peptides” in general under S0
Strongest evidence	Approved label, plus systematic reviews of RCTs	Approved label (tesamorelin only). Small RCTs for the others
Human trials	Dozens: two reviews pooled 18 study groups of older adults and 27 of athletes	Tesamorelin: a phase 3 RCT (Falutz 2007), plus trials such as NCT01263717 (completed) and the phase 2 NCT06554717 (recruiting). MK-677: NCT00474279 (completed)
Last checked	2026-11-11	2026-11-11

Peptides vs HGH at a glance

Feature	HGH (somatropin)	GH-releasing peptides
What it is	Lab-made human growth hormone	Short peptides that trigger the body’s own GH release
Class	Hormone replacement	GHRH analogs (sermorelin, tesamorelin, CJC-1295) and ghrelin mimetics (ipamorelin, GHRP-2, MK-677)
How it acts	Is the hormone	Stimulates the pituitary through GHRH or ghrelin receptors
Needs a working pituitary?	No	Yes. Tesamorelin is contraindicated when the hypothalamic-pituitary axis is disrupted
Main research focus	GH deficiency, aging, sport	HIV belly fat, aging, body composition, child growth
Human evidence	Many RCTs; two systematic reviews	One phase 3 program (tesamorelin); small RCTs for the others
Approval	Approved (GH deficiency and other label uses)	Tesamorelin only; sermorelin discontinued
WADA	Prohibited (S2)	Prohibited (S2)
Routes studied	Injection	Injection; MK-677 by mouth
Timelines in studies	8 weeks (athletes) to about 27 weeks on average (older adults)	16 weeks (GHRH analog) to 1 year (MK-677)
Main safety concerns	Edema, joint pain, carpal tunnel, glucose intolerance	The same, plus appetite gain (MK-677) and injection-site reactions

What is HGH?

Human growth hormone is made by the pituitary gland. Much of its effect runs through IGF-1 (insulin-like growth factor 1), a hormone the liver makes in response to GH. Somatropin is the lab-made version of GH. One brand, Genotropin, is approved to replace GH in two groups of adults: those whose deficiency comes from pituitary or hypothalamic disease, surgery or radiation, and those whose deficiency began in childhood (Approved label). US law treats HGH unusually strictly. Knowingly distributing it for any use other than an FDA-authorized medical use on a physician’s order can bring up to 5 years in prison, or 10 years if a minor is involved (21 U.S.C. 333(e)).

What are GH-releasing peptides?

When people compare “peptides” with HGH, they usually mean GH secretagogues: compounds that make the pituitary release more of its own GH. A 2026 review sorts them into three groups (Dominikowski 2026):

• GHRH analogs: sermorelin, tesamorelin, CJC-1295
• secretagogues: GHRP-2, GHRP-6, hexarelin, ipamorelin
• the GH fragment AOD-9604

MK-677 (ibutamoren) is an oral ghrelin mimetic (Nass 2008) that is usually grouped with these peptides. Tesamorelin is the only one with an FDA approval (Approved label). The three-way ipamorelin vs sermorelin vs tesamorelin comparison covers how the peptides differ from each other.

How they work differently

• HGH: supplies the hormone directly, so it can replace GH when the pituitary cannot make enough (Approved label).
  GHRH peptides: tesamorelin “binds and stimulates human GRF receptors with similar potency as the endogenous GRF” (Approved label).
• HGH: works without the pituitary’s help.
  Peptides: depend on how well the pituitary responds. In 7 children with hypothalamic GH deficiency, GHRH gave little benefit in five. Their growth then reached a mean of 8.5 cm a year on HGH (Human case series, n=7).
• Ghrelin mimetics: ipamorelin (Beck 2014) and MK-677 (Nass 2008) act on the ghrelin receptor. Increased appetite was a reported side effect of MK-677.
• Long-acting GHRH: a single injection of CJC-1295 raised GH 2- to 10-fold for 6 days or more. It raised IGF-1 1.5- to 3-fold for 9–11 days (Human RCTs, healthy adults aged 21–61). The CJC-1295 with vs without DAC comparison explains the two forms.

Evidence head-to-head

The figures below come from separate trials in different groups of people. They are cross-trial numbers, not head-to-head results.

Outcome	HGH best evidence	Peptide best evidence
Lean mass	+2.1 kg in older adults. Human RCTs, review, n=220 (Liu 2007)	MK-677: +1.1 kg, vs −0.5 kg on placebo. Human RCT, n=65 (Nass 2008)
Fat	Fat mass −2.1 kg, weight unchanged. Human RCTs, n=220 (Liu 2007)	Tesamorelin: visceral fat −15.2%, vs +5.0% on placebo. Human RCT, n=412 (Falutz 2007)
Strength, performance	No strength gain. Sprint capacity +3.9%. Human RCT, n=96 (Meinhardt 2010)	No performance trial found
Child growth (GH deficiency)	Approved use (label)	Oral LUM-201: growth within 1.8 cm a year of the HGH arm. The trial was not powered to show non-inferiority. Human phase 2 (Lumos 2023)
Skin, well-being	Not reported in the cited reviews	GHRH(1-29) analog: thicker skin. Better well-being and libido in men. Human trial, n=19 (Khorram 1997)
Recovery after surgery	Not studied in the cited trials	Ipamorelin: no significant effect on time to first meal. Human RCT, n=114 (Beck 2014)
Glucose	More new-onset diabetes and impaired fasting glucose (Liu 2007)	MK-677: fasting glucose +0.3 mmol/L. Tesamorelin: no significant glycemic difference

Tesamorelin, sermorelin, CJC-1295 and ipamorelin vs HGH

• Tesamorelin: the strongest data, for belly fat in HIV lipodystrophy. This is an approved use, backed by a 412-person trial. Its label also says it “is not indicated for weight loss management as it has a weight neutral effect” (Approved label).
• Sermorelin: was once approved to treat children with idiopathic GH deficiency (FDA notice). In older adults, a closely related GHRH(1-29) analog raised GH by 107% in men and 70% in women. It raised IGF-1 by 28% (Human trial, n=19).
• CJC-1295: has hormone-level data only.
• Ipamorelin: its one published phase 2 trial missed its main goal.

More detail is in the hexarelin vs ipamorelin vs tesamorelin comparison, the MK-677 vs ipamorelin comparison and the tesamorelin vs CJC-1295 + ipamorelin comparison.

We searched PubMed (via Europe PMC) and ClinicalTrials.gov on 2026-11-11. Every direct comparison with HGH that turned up was in children with GH deficiency. No adult head-to-head trial was found.

Which fits which goal?

• HGH has more evidence for treating diagnosed GH deficiency in adults and children, which is an approved use. It also has more evidence for raising lean mass. Two reviews found the same 2.1 kg gain in older adults and in young athletes, though in athletes strength did not improve.
• Peptides have more evidence for one specific goal: reducing visceral fat in HIV lipodystrophy. That evidence comes from tesamorelin’s phase 3 trial.
• Neither has good evidence for claims about strength, aging or recovery in healthy adults. The HGH performance review concluded that “claims that growth hormone enhances physical performance are not supported by the scientific literature” (Liu 2008). No performance trial of a GH-releasing peptide was found.

Whether either suits a given person depends on testing for GH deficiency and on medical history. A clinician is the person to decide.

Can they be combined?

No controlled human study of the combination was found on PubMed or ClinicalTrials.gov (searched 2026-11-11). The ClinicalTrials.gov search returned only studies of one agent or the other (ClinicalTrials.gov). Both raise IGF-1, and both labels warn about fluid retention and glucose intolerance (Egrifta WR label). So a combination would stack the same known risks, with no trial data on any added benefit.

Safety and regulatory status

HGH, US: the label warns of:

• increased mortality in acute critical illness
• a higher risk of a second tumor in childhood cancer survivors treated with head radiation
• reduced insulin sensitivity
• intracranial hypertension
• fluid retention

In the first six months of adult GH-deficiency trials, 17.5% of patients had peripheral swelling and 17.3% had joint pain (Approved label). In healthy older adults, people given HGH had more soft-tissue edema, joint pain, carpal tunnel syndrome and gynecomastia (male breast enlargement) (Liu 2007). Distributing HGH outside an authorized medical use is a federal offense (21 U.S.C. 333(e)).

Peptides, US: tesamorelin’s label warns of:

• tumor risk
• raised IGF-1
• fluid retention
• glucose intolerance
• hypersensitivity reactions
• increased mortality in critical illness

The label also states that long-term cardiovascular safety “has not been established” (Approved label). FDA lists MK-677 in Category 2, citing “the potential for congestive heart failure”, and ipamorelin, citing immunogenicity (FDA Category 2 page).

For unregulated GH-axis peptides, a 2026 review lists these reported effects (Dominikowski 2026):

• raised prolactin and cortisol
• appetite changes and abnormal blood sugar
• fluid retention
• muscle and joint pain
• injection-site reactions

A second 2026 review found that “rigorous human safety data are scarce” for unapproved peptides (Mendias 2026).

Sport: HGH, its fragments, GHRH analogs, secretagogues and GHRPs are all prohibited at all times under S2 (WADA). They stay prohibited on the 2027 List (USADA).

Anyone who suspects a side effect from HGH, a GH-releasing peptide or any other drug or product can report it to the FDA through MedWatch.

How long do effects take in studies?

• CJC-1295, hormone levels: a single dose kept IGF-1 raised for 9–11 days (Teichman 2006).
• HGH, performance: the sprint gain appeared after 8 weeks of treatment and faded after stopping (Meinhardt 2010).
• GHRH analog, older adults: changes in skin and lean mass were measured after 16 weeks (Khorram 1997).
• HGH, body composition: treatment in the older-adult trials lasted 27 weeks on average (Liu 2007).
• Tesamorelin, belly fat: the main result was measured at 26 weeks (Falutz 2007). The tesamorelin results timeline breaks it down week by week.